Janssen submits new drug application for HIV therapy

J&J's (JNJ) Janssen unit files an NDA a once-daily antiretroviral combo tablet containing the protease inhibitor darunavir and cobicistat an investigational pharmacokinetic enhancer developed by Gilead Sciences (GILD).

If approved, the product will be marketed under a new brand name. It will eliminate the need to take a separate boosting agent (ritonavir) with darunavir, the most-prescribed HIV protease inhibitor in the U.S.

From other sites
Comments (2)
  • MintyFresh32
    , contributor
    Comments (412) | Send Message
    I've said several times before that JNJ is such a giant that any particular new drug or product is unlikely to move the needle significantly, in terms of earnings or share price growth. But in aggregate, these are the types of moves that make JNJ one of the most successful companies on the planet. Sounds like this drug could simplify treatment for lots of patients and hence could be very desirable. Join great forum discussion of JNJ as a dividend growth machine here: http://bit.ly/1givIml.
    1 Apr 2014, 10:27 AM Reply Like
  • MineMan
    , contributor
    Comments (601) | Send Message
    How will Sangamo Biosciences's SB-728-T therapeutic affect sales of ART drugs?
    Seems to me that GILD and other rettroviral drug makers should begin to hear footsteps. Just as CELG in Melanoma. Addressing diseases that have current costs of treatments, especially high cost of treatments. Are in jeopardy of being replaced by "functional cures" or eventually "cures".
    Something to consider.
    1 Apr 2014, 10:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs